Designing peptide receptor agonists and antagonists

Nature Reviews Drug Discovery

Volumn 1, Issue 11, 2002, Pages 847-858

  Hruby, Victor J ^a  

^a University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; CALCITONIN; CELL SURFACE RECEPTOR; CYTOKINE; DELTORPHIN; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GLUCAGON DERIVATIVE; GONADORELIN ANTAGONIST; GROWTH FACTOR; INSULIN DERIVATIVE; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN; MEMBRANE PROTEIN; METENKEPHALIN; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NEUROTRANSMITTER; OPIATE AGONIST; OPIATE ANTAGONIST; OXYTOCIN; OXYTOCIN DERIVATIVE; PEPTIDE DERIVATIVE; POLYPEPTIDE; PROTEIN PRECURSOR; SEROTONIN UPTAKE INHIBITOR; SIGMA OPIATE RECEPTOR; SOMATOSTATIN; SYNTHETIC PEPTIDE; UNINDEXED DRUG; UTEROTONIC AGENT; LIGAND; RECEPTOR;

CELL FUNCTION; DRUG DESIGN; DRUG RECEPTOR BINDING; HUMAN; IMMUNE RESPONSE; MOLECULAR DYNAMICS; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; METHODOLOGY; PEPTIDE SYNTHESIS; PHARMACEUTICS;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; PEPTIDE BIOSYNTHESIS; RECEPTORS, PEPTIDE; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036834372     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd939     Document Type: Review

References (69)

1. Rudinger, J. in Drug Design Vol. 2 (ed. Ariens, J.) 319-419 (Academic, New York, 1971).
2. Hruby V. J. in Topics in Molecular Pharmacology (eds Burgen, A. S. V. & Roberts, G. C. K.) 99-126 (Elsevier North Holland, Amsterdam, 1981).
3. Kessler, H. Conformation and biological activity of cyclic peptides. Angew. Chemie Int. Edn Engl. 21, 512-521 (1982).
4. Hruby, V. J. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sciences 31, 189-199 (1982).
5. Hirschmann, R. et al. De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing β-D-glucose as a novel scaffolding. J. Am. Chem. Soc. 115, 12550-12568 (1993).
6. Yang, L. et al. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl Acad. Sci. USA 95, 10836-10841 (1998).
7. Pasternak, A. et al. Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg. Med. Chem. Lett. 9, 491-496 (1999).
8. Liao, S. et al. De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the δ-opioid receptor. J. Med. Chem. 41, 4767-4776 (1998).
9. Shenderovich, M. D., Liao, S., Qian, X. & Hruby, V. J. A three-dimensional model of the δ-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands. Biopolymers 53, 565-580 (2000).
10. Hruby, V. J., Al-Obeidi, F. & Kazmierski, W. M. Emerging approaches in the molecular design of receptor selective peptide ligands: conformational, topographical and dynamic considerations. Biochemical J. 268, 249-262 (1990).
11. Hirschmann, R. Medicinal chemistry in the golden age of biology. Lessons from peptide and steroid research. Angew. Chemie Int. Edn Engl. 30, 1278-1301 (1991).
12. Rizo, J. & Gierasch, L. M. Constrained peptides: models of bioactive peptides and protein substructures. Annu. Rev. Biochem. 61, 387-418 (1992).
13. Hruby, V. J. Conformational and topographical considerations in the design of biologically active peptides, Biopolymers 33, 1073-1082 (1993).
14. Marshall, G. R. A hierarchical approach to peptidomimetic design. Tetrahedron 49, 3547-3555 (1993).
15. Farfie, D. P., Abbenante, G. & March, D. R. Macrocyclic peptidomimetics - forcing peptides into boactive conformations. Curr. Med. Chem. 2, 654-686 (1995).
16. Vermey, P. & Block, D. New peptide and protein drugs. Pharm. World Sci. 18, 87-93 (1996).
17. Hruby V. J. & Balse, P. M. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem. 7, 945-970 (2000).
18. Hruby, V. J. Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind-body problem. Acc. Chem. Res. 34, 389-397 (2001).
19. Spiegel, A. M. Genetic basis of endocrine disease: mutations in G-proteins and G-protein-coupled receptors in endocrine disease. J. Clin. Endocrinol. Metab. 81, 2434-2442 (1996).
20. Salamon, Z. et al. Plasmon resonance studies of agonist/antagonist binding to the human δ-opioid receptor: new structural insights into receptor-ligand interactions. Biophys. J. 79, 2463-2474 (2000).
21. Salamon, Z., Alves, I., Cowell, S., Hruby, V. J. & Tollin, G. in Peptides: The Wave of the Future (eds Lebl, M. & Houghten, R. A.) 297-298 (Am. Peptide Soc., San Diego, 2001).
22. Ramachandran, G. N., Ramakrishnan, C. & Sasisekharan, V Stereochemistry of polypeptide chain configurations. J. Mol. Biol. 7, 95-99 (1963).
23. Ramachandran, G. N. & Sasisekharan, V. Conformation of polypeptides and proteins. Adv. Protein Chem. 23, 283-438 (1968).
24. Marshall, G. R. & Bosshard, H. E. Angiotensin II. Biologically active conformation. Circ. Res. 9 (Suppl. 2), 143-150 (1972).
25. Toniolo, C. Conformationally restricted peptides through short-range cyclizations. Int. J. Peptide Protein Res. 35, 287-300 (1990).
26. Spatola, A. in Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins Vol. 7 (ed, Weinstein, B.) 267-357 (Marcel Dekker, New York, 1983).
27. Hruby, V. J. & Gehrig, C. A. Recent developments in the design of receptor specific opioid peptides. Med. Res. Rev. 9, 343-401 (1989).
28. Mosberg, H. I. et al. Bis-penicillamine enkephalins possess highly improved specificity toward δ-opioid receptors. Proc. Natl Acad. Sci. USA 80, 5871-5874 (1983).
29. 5]enkephalin and two halogenated analogues after intravenous administration. J. Pharmacol. Exp. Therap. 259, 1109-1117 (1991).
30. 2.5]enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers. J. Neurochem. 66, 1289-1299 (1996).
31. 5]-enkephalin in aqueous solution determined by NMR and energy minimization calculations. J. Am. Chem. Soc. 110, 3351-3359 (1988).
32. 5]enkephalin, a highly potent, δ-opioid receptor selective compound: comparisons with proposed solution conformations. J. Am. Chem. Soc. 116, 7523-7531 (1994).
33. Shenderovich, M. D., Liao, S,, Qian, X. & Hruby, V. J. A three dimensional model of the δ-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands. Biopolymers 53, 565-580 (2000).
34. Hruby, V. J., Li, G., Haskell-Luevano, C. & Shenderovich, M. D. Design of peptides, proteins, and peptidomimetics in Chi space. Biopolymers 43, 219-266 (1997).
35. Gibson, S. E., Guillo, N. & Tozer, M. J. Towards control of χ-space: conformationally constrained analogs of Phe, Tyr, Trp and His. Tetrahedron 55, 585-615 (1999).
36. Qian, X. et al. Probing the stereochemical requirements for receptor recognition of δ-opioid agonists through topographic modifications in position 1. J. Am. Chem. Soc. 118, 7280-7290 (1996)
37. 4]deltorphin analogues. J. Pharmacol. Exp. Therap. 293, 151-158 (2000).
38. Hruby, V. J. Strategies in the development of peptide antagonists. Prog. Brain Res. 92, 215-224 (1992).
39. Cowell, S. M., Balse-Srinivasan, P. M., & Ahn, J.-M. & Hruby V. J. Design and synthesis of peptide antagonists and inverse agonists for G-protein coupled receptors. Methods Enzymol. 343, 49-72 (2002).
40. Terrett, N. K. Combinatorial Chemistry (Oxford Univ. Press, Oxford, 1998).
41. Hruby, V. J. in The Practice of Medicinal Chemistry Ch. 9 (ed. Wermuth, C. G.) 135-151 (Academic, London, 1996).
42. Yu, J. & Smith, G. P. Affinity maturation of phage-displayed peptide ligands. Methods Enzymol. 267, 3-27 (1996).
43. Schwyzer, R. ACTH: a short introductory review. Ann. N. Y. Acad. Sci. 297, 3-25 (1977).
44. Yamashiro, D. & Li, C. H. in The Peptides: Analysis, Synthesis, Biology Vol. 6. (eds Udenfriend, S. & Meienhofer, J.) 191-217 (Academic, New York, 1984).
45. Lee, N. M. & Smith, A. P. A protein-lipid model of the opiate receptor. Life Sci. 26, 1459-1464 (1980).
46. Garzia, R., Yamashiro, D., Hammonds, G. R. Jr, Ji, G. & Li, C. H. Synthesis and properties of human β-endorphin(1-17) and its analogs. Int. J. Peptide Protein Res. 19, 432-435 (1982).
47. Ferrara, P. & Li, C. H. β-Endorphin interaction of synthetic analogs having different chain lengths with morphine and enkephalin receptors in rat brain membranes. Int. J. Peptide Protein Res. 19, 259-262 (1982).
48. Hruby, V. J., Wright, D. E., Lin, M. C. & Rodbell, M. Semisynthetic glucagon derivatives for structure-function studies. Metabolism 25 (Suppl. 1), 1323-1325 (1976).
49. Bregman, M. D., Trivedi, D. B. & Hruby, V. J. Glucagon amino groups: evaluation of modifications leading to antagonism and agonism. J. Biol. Chem. 255, 11725-11733 (1980).
50. Johnson, D. G., Goebel, C. U., Hruby, V. J., Bregman, M. D. & Trivedi, D. B. Decrease in hyperglycemia of diabetic rats by a glucagon receptor antagonist. Science 215, 1115-1116 (1982).
51. 9]glucagon amide: a newly designed 'pure' glucagon antagonist. Bioorg. Med. Chem. Lett. 5, 1849-1852 (1995).
52. Hruby, V. J., Ahn, J.-M. & Trivedi, D. The design and biological activities of glucagon agonists and antagonists, and their use in examining the mechanisms of glucose action. Curr. Med. Chem. 1, 199-215 (2001).
53. Unson, C. G., Andreu, D., Gurgenda, E. M. & Merrifield, R. B. Synthetic peptide antagonists of glucagon. Proc. Natl Acad. Sci. USA 84, 4083-4087 (1987).
54. 2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137, 3316-3322 (1996).
55. Hruby, V. J., Chow, M.-S. & Smith, D. D. Conformational and structural considerations in oxytocin-receptor binding and biological activity. Annu. Rev. Pharmacol. Toxicol. 30, 501-534 (1990).
56. Lebl, M. in Handbook of Neurohypophyseal Hormone Analogs Vol. 2 Part 1 (eds Jost, K., Lebl, M. & Brtnik, F.) 17-74 (CRC, Boca Raton, 1987).
57. Manning, M. et al. in Peptides 1988 (eds Jung, G. & Bayer, E.) 552-555 (Walter de Guyter, Berlin, 1989).
58. Hill, P. S., Smith, D. D., Slaninová, J. & Hruby, V. J. Bicyclization of a weak oxytocin agonist produces a highly potent oxytocin antagonist. J. Am. Chem. Soc. 112, 3110-3113 (1990).
59. Meraldi, J.-P., Hruby, V. J. & Brewster, A. I. R. Relative conformational rigidity in oxytocin and [1-penicillamine]-oxytocin: a proposal for the relationship of conformational flexibility to peptide hormone agonism and antagonism. Proc. Natl Acad. Sci. USA 74, 1373-1377 (1977).
60. Wood, S. P. et al. crystal structure analysis of deamino-oxytocin: conformational flexibility and receptor binding. Science 232, 633-636 (1986).
61. Hruby, V. J. Implications of the X-ray structure of deamino-oxytocin to agonist/antagonist-receptor interactions. Trends Pharmacol. Sci. 8, 336-339 (1987).
62. Shenderovich, M. D., Kövér, K. E., Wilke, S., Collins, N. & Hruby, V. J. Solution conformations of potent bicyclic antagonists of oxytocin by nuclear magnetic resonance spectroscopy and molecular dynamics simulations. J. Am. Chem. Soc. 119, 5833-5846 (1997).
63. Liao, S. et al. Substitution of the side-chain constrained amino acids α-methyl-2′,6′-dimethyl-4′-methoxytyrosine in position 2 of a bicyclic oxytocin analogue provides unique insights into the bioactive topography of oxytocin antagonists. J. Am. Chem. Soc. 120, 7393-7394 (1998).
64. Cho, N. et al. Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J. Med. Chem. 41, 4190-4195 (1998).
65. Cho, N. et al. Thieno[2,3-d]pyrimidine-3-acetic acids. A new class of nonpeptide endothelin receptor antagonists. Chem. Pharm. Bull. 46, 1724-1737 (1998).
66. Henry, J. A., Horwell, D. C., Meecham, K. G. & Rees, D. C. A structure-affinity study of the amino acid side-chains in neurotensin: N and C terminal deletions and Ala-scan. Bioorg. Med. Chem. Lett. 3, 949-952 (1993).
67. 7]-α-melanocyte stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc. Natl Acad. Sci. USA 77, 5754-5758 (1980).
68. Sawyer, T. K., Hruby, V. J., Darman, P. S. & Hadley, M. E. [4-Half-cystine,10-half-cystine]-α-melanocyte stimulating hormone: a cyclic α-melanotropin exhibiting superagonist biological activity. Proc. Natl Acad. Sci. USA 79, 1751-1755 (1982).
69. Ahn, J.-M. et al. A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning. J. Med. Chem. 44, 3109-3116 (2001).